SAB Biotherapeutics, Inc. (SABSW) stock
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
SAB Biotherapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$34.63M. For fiscal 2025 it was -$45.71M. The highest annual figure on record is -$2.73M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.71M | – |
| FY2024 | Dec 31, 2024 | -$34.63M | – |
| FY2023 | Dec 31, 2023 | -$25.32M | – |
| FY2022 | Dec 31, 2022 | -$25.63M | – |
| FY2021 | Dec 31, 2021 | -$8.96M | – |
| FY2020 | Dec 31, 2020 | -$2.73M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.25M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.59M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.63M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.00M | -1504.7% |
| Q2 FY2022 | Jun 30, 2022 | -$5.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.90M | -244.1% |
| Q4 FY2021 | Dec 31, 2021 | -$7.24M | – |
| Q3 FY2021 | Sep 30, 2021 | $569.32K | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.85M | – |
| Q1 FY2021 | Mar 31, 2021 | $7.56M | – |